AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01665651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zuogui granules placebo
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study NCT01039454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK598809 Capsules
Description: GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
Study NCT01039454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809 Placebo Capsules
Description: Treatment of substance dependence and potentially other impulse control disorders.
Study NCT03068884 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cathodal Transcranial direct current stimulation
Description: Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
Study NCT03068884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal Transcranial direct current stimulation
Description: Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
Study NCT03068884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Tyrosine
Description: Administration of 2 grams tyrosine
Study NCT03068884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: L-Tyrosine
Description: Administration of 2 grams tyrosine
Study NCT03068884 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation (sham)
Description: Sham tDCS
Study NCT03068884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (sham)
Description: Sham tDCS
Study NCT03068884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellulose (placebo)
Description: Administration of 2 grams cellulose
Study NCT03068884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Cellulose (placebo)
Description: Administration of 2 grams cellulose
Study NCT03493321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF with Theracal
Description: using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
Study NCT02568007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Study NCT02736760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy using Methylaminolevulinate (MAL)
Description: In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months.
Study NCT02736760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
Study NCT00659022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neo-adjuvant treatment with bevacizumab
Description: neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
Study NCT00659022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant treatment with capecitabine and oxaliplatin
Description: neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
Study NCT00683735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily in the morning
Study NCT00683735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: up to 2000 mg/day
Study NCT00683735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500mg 1-0-0-0
Study NCT00683735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500mg 1-0-0-0
Study NCT00659022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin
Description: neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
Study NCT00647647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets 250 mg
Description: 250mg, single dose fasting
Study NCT00647647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil® Tablets 250 mg
Description: 250mg, single dose fasting
Study NCT02884453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 1 mg
Description: Oral alprazolam 1 mg + Inhaled placebo
Study NCT01769027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline+Antibiotic (penicillin/azithromycin)
Description: 12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
Study NCT01769027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline+placebo
Description: 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
Study NCT00683735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100mg 1-0-0-0
Study NCT00683735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg 1-0-0-0
Study NCT01749761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BioLogic RR
Description: Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
Study NCT01749761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis without biofeedback
Description: patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
Study NCT01726023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Description: Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
Study NCT01726023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: Metronidazole 500mg/100ml solution for infusion
Study NCT01726023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem powder for solution for infusion 1000mg
Study NCT02601053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dull movie
Description: A dull movie (duration approximately 90 minutes)
Study NCT01769027 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
Study NCT02477748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDX
Description: Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
Study NCT02477748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet PO, taken once daily for 10 weeks.
Study NCT02601053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dull movie
Description: A dull movie (duration approximately 90 minutes)
Study NCT02601053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scary (horrifying) movie
Description: A scary movie (duration approximately 90 minutes)
Study NCT02601053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scary (horrifying) movie
Description: A scary movie (duration approximately 90 minutes)
Study NCT02601053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate measurement
Description: Heart rate measurement using a actiheart device
Study NCT02601053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate measurement
Description: Heart rate measurement using a actiheart device
Study NCT02844010 — intervention group
Intervention type: OTHER
Intervention: weighing
Study NCT04225286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human breast milk
Description: Intranasal human breast milk
Study NCT00710099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: systemic absorption of sildenafil
Study NCT00710099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprussiate iontophoresis
Description: nitroprussiate iontophoresis
Study NCT04154722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: inj meropenum for 10 days
Study NCT04154722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem Injection
Description: inj meropenum for 10 days
Study NCT04154722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Powder
Description: syp azithromycin for10days
Study NCT03896191 — intervention group
Intervention type: PROCEDURE
Intervention: Revision TKR surgery
Description: This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
Study NCT03896191 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
Study NCT03034161 — intervention group
Intervention type: DEVICE
Intervention: Thermal imaging
Description: Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
Study NCT00885677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic CareLink® Network
Description: Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur.
Study NCT01404052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
Study NCT01404052 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
Study NCT04403399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
Study NCT04403399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
Study NCT03800225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair
Description: Anterior ligament repair with internal brace.
Study NCT03800225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair
Description: Anterior ligament repair with internal brace.
Study NCT04027257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Together and Read (STAR)
Description: STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
Study NCT00498628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate- taken daily, for 12 weeks
Study NCT02158481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A capsule containing both polyphenols and carotenoids
Study NCT00498628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03364504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine collection
Description: 3 urine collections during 24 hours
Study NCT03868696 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: MUA with sham ultrasound
Description: Standard MUA with sham ultrasound
Study NCT03868696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MUA with active ultrasound
Description: Standard MUA guided by ultrasound
Study NCT01483170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablets Fexinidazole
Description: Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
Study NCT01483170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo fexinidazole
Study NCT03419819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Sphere
Description: PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
Study NCT04476784 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses
Study NCT04476784 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT04476784 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution
Study NCT01006733 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic
Description: The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
Study NCT01006733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target INR 1.8
Description: We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
Study NCT02134184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2012-2013 Formula NDC No 498281-012-50
Description: This vaccine is given intramuscularly
Study NCT00841815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate
Description: 10 mg Tablet
Study NCT00841815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc®
Description: 10 mg Tablet
Study NCT02158481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Placebo intervention
Study NCT02652754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Granexin® gel
Description: Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
Study NCT00437983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PS-Omega3
Description: Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
Study NCT00437983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
Study NCT00822042 — intervention group
Intervention type: OTHER
Intervention: Samples and procedures
Description: * Scanner, histomorphometry : at the inclusion and M3 visits~* whole blood samples, cytoponction : at the inclusion and M3 visits
Study NCT03676283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based psycho-educational support for family caregivers
Description: A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
Study NCT04480008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Living Program
Description: Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
Study NCT04249531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Inhalation Dry Powder
Description: Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
Study NCT04249531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin Injectable Product
Description: patient wil receive one dose of 400 mg amikacine intravenously in week 1
Study NCT02404220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Study NCT02404220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT02404220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02404220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNS Prophylaxis
Study NCT01780571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP 5 cm H2O + PSV 5 cm H2O
Description: Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
Study NCT03719209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthVoyager
Description: HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
Study NCT03719209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Practice
Description: Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
Study NCT01070251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participatory parent-focused intervention
Description: Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
Study NCT01070251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: State-sponsored PA program
Description: Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer